Mark Bertagnolli profile page

Mark Bertagnolli is the Chief Operating Officer of ViroMissile and serves on its board of directors, having served previously as the Company’s Chief Business Officer. Before ViroMissile, Mark was founder of Amitech Therapeutic Solutions, a small molecule biotechnology company, after serving as Genelux Corporation’s Chief Business Officer, where he worked with ViroMissile’s founder, Dr. Nanhai George Chen. Prior to Genelux, Mark worked on the buy-side of Wall Street, where he founded the global technology hedge fund at FrontPoint Partners, a Morgan Stanley company, and prior to that Mark was a partner at Andor Capital Management, a fund that split from Pequot Capital Management, where Mark joined in 2000 following a year on the sell-side at Salomon Smith Barney. Prior to his time in the investment community, Mark worked at both Texas Instruments and Philips Semiconductor. Mark served for 5 years as a nuclear submarine officer in the US Navy, earning the designation Nuclear Engineer by the Naval Reactors division of the DOE. Mark earned a Bachelor of Science in Aerospace Engineering, cum laude, from the University of Michigan, Ann Arbor, and is a Certified Director by NACD.